These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 35689489)
21. When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multi-center research. Ren J; Lin K; Xu J; Lu Q; Luo Y; Lin C; Lu J; Weng Y; Zhang Y; Chen Z; Gale RP; Hu J; Yang T Clin Transplant; 2024 Jan; 38(1):e15195. PubMed ID: 37987525 [TBL] [Abstract][Full Text] [Related]
22. Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation. Shin J; Dan K; Han D; Kim JW; Kim KK; Koh Y; Shin DY; Hong J; Yoon SS; Park S; Song SH; Kim I Blood Cells Mol Dis; 2019 Feb; 74():5-12. PubMed ID: 30344086 [TBL] [Abstract][Full Text] [Related]
23. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report. Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249 [TBL] [Abstract][Full Text] [Related]
24. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628). von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies. Zhang MY; Zhao P; Zhang Y; Wang JS PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125 [TBL] [Abstract][Full Text] [Related]
26. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Major-Monfried H; Renteria AS; Pawarode A; Reddy P; Ayuk F; Holler E; Efebera YA; Hogan WJ; Wölfl M; Qayed M; Hexner EO; Wudhikarn K; Ordemann R; Young R; Shah J; Hartwell MJ; Chaudhry MS; Aziz M; Etra A; Yanik GA; Kröger N; Weber D; Chen YB; Nakamura R; Rösler W; Kitko CL; Harris AC; Pulsipher M; Reshef R; Kowalyk S; Morales G; Torres I; Özbek U; Ferrara JLM; Levine JE Blood; 2018 Jun; 131(25):2846-2855. PubMed ID: 29545329 [TBL] [Abstract][Full Text] [Related]
27. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281 [TBL] [Abstract][Full Text] [Related]
28. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813 [TBL] [Abstract][Full Text] [Related]
29. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease. Belina ME; Driscoll TA; Blanchard SK; Cardones AR Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308 [TBL] [Abstract][Full Text] [Related]
30. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects. Barbour AM; Punwani N; Epstein N; Landman R; Cimino E; Yuska B; Wang P; He K; Chen X; Yeleswaram S J Clin Pharmacol; 2019 Dec; 59(12):1641-1647. PubMed ID: 31282592 [TBL] [Abstract][Full Text] [Related]
31. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor. Murashige N; Kami M; Mori S; Katayama Y; Kobayashi K; Onishi Y; Hori A; Kishi Y; Hamaki T; Tajima K; Kanda Y; Tanosaki R; Takaue Y Am J Hematol; 2008 Aug; 83(8):630-4. PubMed ID: 18454459 [TBL] [Abstract][Full Text] [Related]
32. Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Aladağ Karakulak E; Demİroğlu H; Malkan UY; Akman U; Göker H; Büyükaşik Y Turk J Med Sci; 2021 Feb; 51(1):355-358. PubMed ID: 32927932 [TBL] [Abstract][Full Text] [Related]
33. Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models. Huarte E; Peel M; Juvekar A; Dubé P; Sarah S; Stephens L; Stewart B; Long B; Czerniak P; Oliver J; Smith P Immunotherapy; 2021 Aug; 13(12):977-987. PubMed ID: 34184542 [No Abstract] [Full Text] [Related]